Hunting for rare mutations that cause dementia, researchers have spotted, but not yet snagged, some tantalizing candidates.
Tau ligands for PET scans were among the hot topics at the Alzheimer’s Association International Conference in Boston.
Mass spectrometry data show how γ-secretase modulators skew APP processing toward Aβ40 rather than Aβ42, without upsetting cleavage of other substrates.
Neural activity sends amyloid precursor proteins into endosomes where β-secretase drives Alzheimer pathology.
Struggles to develop therapeutic antibodies for prion disease teach scientists how prion protein may kill neurons.
Removing a key component of the innate immune system worsens amyloid deposition but improves memory in mice that model Alzheimer's pathology.
Protein strains may underlie different tauopathies, according to researchers presented at this year's AAIC meeting in Boston.
Speakers at Alzheimer’s conference reviewed planned Phase 1 and prevention trials and preclinical studies.
A DNA-based Aβ vaccine appears safe and produces a strong immune response in monkeys, suggesting it could work in people.
Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Knocking down tau expression in adult mice diminishes induced seizures.
Neurons clear misfolded proteins at different speeds. Is this why some brain regions are more vulnerable to neurodegeneration than others?
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
A study suggests that genes involved in Aβ production and endocytosis mediate ApoE4’s role in Alzheimer’s disease.
At AAIC 2013, researchers present the latest genetic risk factors for Alzheimer's disease.